Vabysmo achieved positive safety and efficacy results in two global phase 3 studies investigating its use for macular edema due to branch and central retinal vein occlusion, according to a press release from Genentech.
The bispecific antibody is designed to stabilize blood vessels by blocking disease pathways involving angiopoietin-2 and VEGF-A, which may contribute to vision loss by destabilizing blood vessels and increasing inflammation.
The BALATON and COMINO studies met their primary endpoints, with Vabysmo (faricimab-svoa) injections every 4 weeks for up to 24 weeks achieving